388 related articles for article (PubMed ID: 24593945)
1. PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease.
Barbiero JK; Santiago R; Tonin FS; Boschen S; da Silva LM; Werner MF; da Cunha C; Lima MM; Vital MA
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Aug; 53():35-44. PubMed ID: 24593945
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine.
Barbiero JK; Santiago RM; Persike DS; da Silva Fernandes MJ; Tonin FS; da Cunha C; Lucio Boschen S; Lima MM; Vital MA
Behav Brain Res; 2014 Nov; 274():390-9. PubMed ID: 25127682
[TBL] [Abstract][Full Text] [Related]
3. Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.
Kreisler A; Gelé P; Wiart JF; Lhermitte M; Destée A; Bordet R
Brain Res; 2007 Mar; 1135(1):77-84. PubMed ID: 17196944
[TBL] [Abstract][Full Text] [Related]
4. Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
Kreisler A; Duhamel A; Vanbesien-Mailliot C; Destée A; Bordet R
Behav Pharmacol; 2010 May; 21(3):194-205. PubMed ID: 20440202
[TBL] [Abstract][Full Text] [Related]
5. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
[TBL] [Abstract][Full Text] [Related]
6. Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats.
Capitelli C; Sereniki A; Lima MM; Reksidler AB; Tufik S; Vital MA
Eur J Pharmacol; 2008 Oct; 594(1-3):101-8. PubMed ID: 18674531
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effects of madecassoside in early stage of Parkinson's disease induced by MPTP in rats.
Xu CL; Qu R; Zhang J; Li LF; Ma SP
Fitoterapia; 2013 Oct; 90():112-8. PubMed ID: 23876367
[TBL] [Abstract][Full Text] [Related]
8. Involvement of NMDA receptors in both MPTP-induced neuroinflammation and deficits in episodic-like memory in Wistar rats.
Wang AL; Liou YM; Pawlak CR; Ho YJ
Behav Brain Res; 2010 Mar; 208(1):38-46. PubMed ID: 19900486
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.
Castro AA; Wiemes BP; Matheus FC; Lapa FR; Viola GG; Santos AR; Tasca CI; Prediger RD
Brain Res; 2013 Jun; 1513():103-16. PubMed ID: 23548600
[TBL] [Abstract][Full Text] [Related]
10. Baicalein protects the brain against neuron impairments induced by MPTP in C57BL/6 mice.
Mu X; He GR; Yuan X; Li XX; Du GH
Pharmacol Biochem Behav; 2011 Apr; 98(2):286-91. PubMed ID: 21262257
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system.
Guo Z; Xu S; Du N; Liu J; Huang Y; Han M
Neurosci Lett; 2016 Mar; 616():152-9. PubMed ID: 26827716
[TBL] [Abstract][Full Text] [Related]
12. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732
[TBL] [Abstract][Full Text] [Related]
13. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.
Gibrat C; Saint-Pierre M; Bousquet M; Lévesque D; Rouillard C; Cicchetti F
J Neurochem; 2009 Jun; 109(5):1469-82. PubMed ID: 19457163
[TBL] [Abstract][Full Text] [Related]
14. Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease.
Garrido-Gil P; Joglar B; Rodriguez-Perez AI; Guerra MJ; Labandeira-Garcia JL
J Neuroinflammation; 2012 Feb; 9():38. PubMed ID: 22356806
[TBL] [Abstract][Full Text] [Related]
15. Fenofibrate promotes neuroprotection in a model of rotenone-induced Parkinson's disease.
Barbiero JK; Ramos DC; Boschen S; Bassani T; Da Cunha C; Vital MABF
Behav Pharmacol; 2022 Dec; 33(8):513-526. PubMed ID: 36094044
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice.
Patil SP; Jain PD; Ghumatkar PJ; Tambe R; Sathaye S
Neuroscience; 2014 Sep; 277():747-54. PubMed ID: 25108167
[TBL] [Abstract][Full Text] [Related]
17. Preventive role of PD-1 on MPTP-induced dopamine depletion in mice.
Jung HW; Son HY; Jin GZ; Park YK
Cell Biochem Funct; 2010 Apr; 28(3):217-23. PubMed ID: 20186864
[TBL] [Abstract][Full Text] [Related]
18. Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP model of Parkinson's disease in rats.
Bisht R; Kaur B; Gupta H; Prakash A
Neurotoxicology; 2014 Sep; 44():71-9. PubMed ID: 25053526
[TBL] [Abstract][Full Text] [Related]
19. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.
Ghosh A; Kanthasamy A; Joseph J; Anantharam V; Srivastava P; Dranka BP; Kalyanaraman B; Kanthasamy AG
J Neuroinflammation; 2012 Oct; 9():241. PubMed ID: 23092448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
